Biocon Biologics
Highly Engaged Employees
Highly Engaged EmployeesChemicals & Related Products · India · 5K - 10K Employees
View Company Info for Free
Overview
Headquarters
Biocon House Semicon Park Electronics Ci...Phone Number
+91 8067756775Website
www.bioconbiologics.comRevenue
$1.1 BillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
1
1
1
1
1
About Biocon Biologics
Biocon Biologics Limited, a subsidiary of Biocon Limited, is a fully integrated global biosimilars organization. It is leveraging cutting-edge science, innovative tech platforms and advanced research & development capabilities to lower treatment costs while improving healthcare outcomes. It has a strong research pipeline of biosimilar molecules across diabetes, oncology, immunology, and other non-communicable diseases. Six molecules from Biocon Biologics’ portfolio have been taken from lab to market in developed markets like United States, EU, Australia, Canada and Japan.Explore more
Biocon Biologics Org Chart
Get the full picture
Sign in to uncover key details.
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Biocon Biologics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Biocon Biologics recently announced quarterly report
Check out if Biocon Biologics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Biocon Biologics
Click to see if Biocon Biologics had a recent Job posting/layoffs
Biocon Biologics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check if Biocon Biologics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Biocon Biologics has new funding data
Product Launch: Get notified when Biocon Biologics launches new products
Recommended Actions
Reach out to Masked Content who joined Biocon Biologics as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Biocon Biologics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Biocon Biologics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Biocon Biologics.
Biocon Biologics financials insights
Gather financial insights about Biocon Biologics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Debt
$300M
Biocon Biologics Tech Stack
A closer look at the technologies used by Biocon Biologics
See more technologies
Most Recent Scoops
Hiring Plans
Biocon Biologics has more open roles in Operations than it has had at any time in the past 6 months. Technologies mentioned include: Demand Planning, SAP, Kinaxis, and SAP ERP. Areas of expertise include: Document Management, Negotiation Strategies, Risk Management Planning, and Risk Management.
Hiring Plans
Hiring Plans
Biocon Biologics has more open roles in Sales than it has had at any time in the past 12 months. Technologies mentioned include: Microsoft Teams.
Hiring Plans
Left Company
Executive Move
Executive Moves, Left Company
Lateral Move
Executive Move
Executive Moves, Lateral Move
Promotion
Executive Move
Executive Moves, Promotion
Biocon Biologics News & Media
Biocon Biologics to Expand Biosimilar Oncology Portfolio, Outline Strategic Vision at the 2026 J.P. Morgan Healthcare Conference
•New oncology assets to include proposed biosimilars for Trastuzumab/Hyaluronidase combination (Herceptin® SC/Herceptin HYLECTA™), Nivolumab (Opdivo®) and Pembrolizumab (Keytruda®) •Company to outline integration as a wholly owned subsidiary into Biocon Ltd., strengthening its global leadership in biosimilar insulins and GLP 1 peptide generics to cover the full spectrum of diabetes care •New oncology assets to include proposed biosimilars for Trastuzumab/Hyaluronidase combination (Herceptin® SC/Biocon and Regeneron Enter Global Settlement on Aflibercept Biosimilar - JD Supra
On December 13, 2025, Biocon Biologics Ltd. (“Biocon”) and Regeneron Pharmaceuticals, Inc. (“Regeneron”) entered into a license and settlement agreement to dismiss all pending claims in the...Biocon Biologics Reaches Global Settlement to Enable Worldwide Launch of Biosimilar Aflibercept
Biocon Biologics Ltd (BBL), a wholly owned subsidiary of Biocon Ltd (BSE: 532523, NSE: BIOCON), has entered into a settlement and licensing arrangement with Regeneron and Bayer covering Europe and other international markets for its biosimilar Aflibercept (40 mg/ml). This agreement follows a previously announced settlement for the United States and Canada and removes remaining Machine Maker - Latest Manufacturing News | Indian Manufacturing News - Latest Manufacturing News | Indian Manufacturing
Read more news
Top Chemicals & Related Products Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Biocon Biologics
Sign Up For FreeTo access detailed company insights
Biocon Biologics Limited, a subsidiary of Biocon Limited, is a fully integrated global biosimilars organization. It is leveraging cutting-edge science, innovative tech platforms and advanced research & development capabilities to lower treatment costs while improving healthcare outcomes. It has a strong research pipeline of biosimilar molecules acr... Read More
